Additionally, the FDA is recommending that healthcare providers who are prescribing such treatments discuss naloxone’s availability with patients and their caregivers. The agency is also recommending they consider prescribing naloxone to patients receiving medicines that treat opioid use disorder and patients receiving opioid pain medicines who are at increased risk of opioid overdose.
“Today’s action can help further raise awareness about this potentially life-saving treatment for individuals that may be at greater risk of an overdose and those in the community most likely to observe an overdose,” Stephen Hahn, MD, the FDA’s commissioner, said in a July 23 news release.
The new rule comes as the FDA and local communities are working to increase access to naloxone to fight opioid overdoses.
More articles on opioids:
Fatal overdoses hit record high in 2019, CDC data shows
Opioid prescriptions fell in 2019 for 6th consecutive year, AMA finds
Around 20% of pregnant women misused opioids in 2019, CDC reports
Opioid prescriptions fell in 2019 for 6th consecutive year, AMA finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
